MYO News and Press, Myomo Inc. From 11/07/23

Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE American: MYO) ...

2023-11-06 17:35:58 ET Myomo ( NYSE: MYO ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, after market close. The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $4.15M (+4.5% Y/Y). Over the last 1 year, MYO has beaten E...

Public Meeting Scheduled for November 29, 2023 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, t...

Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those su...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for th...

2023-09-22 12:52:13 ET For further details see: CETX, MYO and MORF among mid-day movers

2023-09-12 12:57:49 ET More on Myomo Seeking Alpha’s Quant Rating on Myomo Historical earnings data for Myomo Myomo: Game-Changing Medicare Reimbursement Should Create Lasting Value plans for stock offering, size not disclosed For further detai...

2023-09-12 12:52:44 ET Gainers: Anebulo Pharmaceuticals ( ANEB ) +35% . WeWork ( WE ) +34% . Shengfeng Development Limited ( SFWL ) +29% . AEON Biopharma ( AEON ) +28% . Avalo Therapeutics ( AVTX ) +28% . The Beauty Health Co...

2023-09-05 09:00:00 ET Summary CMS changed their policy to include Myomo's MyoPro devices as a covered product under Medicare. Proposed broad coverage would result in significant operating leverage and sustainable profitability for Myomo. Anemic valuation provides outsized ret...

Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public...